InflaRx receives Nasdaq notice over minimum bid price rule
#InflaRx #Nasdaq #minimum bid price #compliance #delisting #stock price #notice
📌 Key Takeaways
- InflaRx received a Nasdaq notice for non-compliance with the minimum bid price rule.
- The company's stock price has fallen below the required $1.00 threshold.
- InflaRx has 180 days to regain compliance by meeting the minimum bid price.
- Failure to comply could lead to delisting from the Nasdaq stock exchange.
🏷️ Themes
Regulatory Compliance, Stock Market
📚 Related People & Topics
Nasdaq
American stock exchange
Nasdaq Stock Market (National Association of Securities Dealers Automated Quotations) is an American stock exchange, the second-largest by market cap on the list of stock exchanges, and the first fully electronic stock market. The exchange is based in Manhattan, New York City, and is among the most ...
Entity Intersection Graph
Connections for Nasdaq:
View full profileMentioned Entities
Deep Analysis
Why It Matters
This news is critical for InflaRx's investors as it signals a potential loss of listing on the Nasdaq exchange, which could severely impact the company's stock liquidity and market valuation. The notice indicates the company's shares have fallen below the exchange's $1.00 minimum bid price requirement, threatening to force a delisting if not corrected. This development is particularly concerning for stakeholders in the biotechnology sector, as maintaining a listing is often a key metric of corporate health and stability.
Context & Background
- Nasdaq maintains a minimum bid price rule (Rule 5550(a)(2)) requiring listed securities to trade at or above $1.00 per share.
- Biotechnology companies frequently face this challenge due to the high volatility and capital-intensive nature of drug development.
- InflaRx is a clinical-stage biopharmaceutical company focused on anti-inflammatory therapies, specifically its drug Vilobelimab.
- Companies receiving such notices typically receive a grace period of 180 days to regain compliance.
- To meet the requirement, companies often execute a reverse stock split to increase the share price.
What Happens Next
InflaRx will likely file a compliance plan with Nasdaq within the next 180 days, which usually involves executing a reverse stock split to boost the share price above $1.00. If the company successfully executes this split and the price remains compliant, they will avoid delisting. However, if they fail to meet the deadline or the split does not stabilize the price, the company risks being moved to the OTC (Over-the-Counter) market, which generally offers less liquidity and visibility.
Frequently Asked Questions
It is a Nasdaq listing requirement that a security must maintain a minimum bid price of $1.00 per share to remain listed on the exchange.
It is a corporate action where a company reduces the number of its outstanding shares, increasing the price per share proportionally to keep the market capitalization the same.
Delisting can lead to a loss of investor confidence, reduced liquidity for shares, and a potential drop in the stock's valuation as it moves to less regulated markets like the OTC.
InflaRx is a clinical-stage biopharmaceutical company developing anti-inflammatory therapies, with a focus on its drug candidate Vilobelimab for treating inflammatory diseases.